5 ASX All Ords shares starting the new year at 52-week highs
S&P/ASX All Ords Index (ASX: XAO) shares closed higher on the first day of trading for 2025.
The ASX All Ords finished 0.53% higher at 8,465 points on Thursday.
Here are five ASX All Ords shares that started the new year on a positive note with 52-week high prices.
5 ASX All Ords shares that hit 52-week highs on Thursday
Mesoblast Ltd (ASX: MSB)
It's rather fitting that the No. 1 stock among the 5 best-performing ASX All Ords stocks of 2024 started the new year at a four-year high.
The Mesoblast share price reached $3.37 in intraday trading on Thursday.
The ASX biotech closed at $3.35, up 8.06%.
Mesoblast develops drugs for complex diseases. The company did not release any news yesterday.
However, the ASX All Ords stock has been on an upward trajectory since the biotech gained approval from the United States Food and Drug Administration for its lead drug, remestemcel-L, last month.
Branded Ryoncil, the drug is the first approved treatment for steroid-refractory acute graft versus host disease (SR-aGvHD) in children and the first mesenchymal stromal cell (MSC) therapy approved in the US.
Bravura Solutions Ltd (ASX: BVS)
Another ASX All Ords tech share, Bravura Solutions, also clocked a 52-week high yesterday.
On Thursday, the Bravura share price ascended to a three-year high of $2.31. It closed steady at $2.25.
Last month the wealth management software provider upgraded its FY25 guidance. It now expects cash EBITDA of between $33 million and $36 million, which is well up on its previous guidance of $28 million to $32 million. Investors were also pleased to learn that Bravura plans to resume paying dividends this year.
Botanix Pharmaceuticals Ltd (ASX: BOT)
The Botanix Pharmaceuticals share price lifted to a 12-year high of 45.5 cents per share on Thursday.
The ASX All Ords cannabis share closed at 45 cents, up 3.45%.
Botanix is a clinical-stage dermatology company that produces synthetic cannabinoid pharmaceutical products for skin conditions. The company had no news for the market yesterday.
However, last month, Botanix Pharmaceuticals announced that the first prescriptions for its Sofdra topical gel had been shipped to patients following telemedicine diagnoses and insurance approvals.
Sofdra treats excessive underarm sweating in adults and children aged nine years and older.
Botanix will undertake a full commercial launch of Sofdra in the first quarter of this year.
Perenti Ltd (ASX: PRN)
The Perenti share price hit a 52-week peak of $1.44 on Thursday despite no news from the company.
Stock in the ASX All Ords mining operations provider closed at $1.435 per share, up 2.87%.
Appen Ltd (ASX: APX)
ASX All Ords tech share Appen hit a 52-week high of $2.91 in intraday trading on Thursday.
The data sourcing and annotation provider stock finished the day at $2.82 per share, up 6.82%.
The post 5 ASX All Ords shares starting the new year at 52-week highs appeared first on The Motley Fool Australia.
Motley Fool contributor Bronwyn Allen has positions in Appen and Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Appen and Bravura Solutions. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2025